Immunoglobulin Fc-Fusion Proteins
Over the past decades, several monoclonal antibodies (MAbs) and MAb-derivative products have been approved for therapeutic use in the United States. Specifically, one class of antibody derivatives has acquired growing importance: Fc-fusion proteins.
The interest in Fc-fusion proteins lies in the fact that the potential therapeutic value of many proteins — including enzymes, receptors, cytokines, blood factors, and peptides — can be realized by fusing them to the Fc region of human immunoglobulin G.
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing process and therapeutic uses:
- Article “Immunoglobulin Fc-Fusion Proteins Part 1: Their Design and Manufacture”
- Article “Immunoglobulin Fc-Fusion Proteins Part 2: Therapeutic Uses and Clinical Development”
Our experts behind the articles:
- Angela Linderholm
- Steven M. Chamow
Contact us to discover how our team’s comprehensive knowledge in biologics, MAbs, and Mab-derivative products can make a significant difference in your development journey.